Sailaja Kamaraju MD

Dr. Sailaja Kamaraju MD

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in American Society of Clinical Oncology Educational Book
Verified
Journal Article
Closed access
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
JDJeffrey Drope
Jeffrey Drope
RSRengaswamy Sankaranarayanan
Rengaswamy Sankaranarayanan
SSSurendra Shastri
Surendra Shastri
Rising trends in the incidence of cancer in low- and middle-income countries (LMICs) add to the existing challenges with communicable and noncommunicable diseases. While breast and colorectal cancer incidence rates are increasing in LMICs, the incidence of cervical cancer shows a mixed trend, with rising incidence rates in China and sub-Saharan Africa and declining trends in the Indian subcontinent and South America. The increasing frequencies of unhealthy lifestyles, notably less physical activity, obesity, tobacco use, and alcohol consumption are causing a threat to health care in LMICs. Also, poorly developed health systems tend to have inadequate resources to implement early detection and adequate basic treatment. Inequalities in social determinants of health, lack of awareness of cancer and preventive care, lack of efficient referral pathways and patient navigation, and nonexistent or inadequate health care funding can lead to advanced disease presentation at diagnosis. This article provides an overview of opportunities to address cancer control in LMICs, with a focus on tobacco control, vaccination for cervical cancer, novel tools to assist with early detection, and screening for breast and other cancers.

15 November 2018 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
YSYushu Shi
Yushu Shi
ESElizabeth Smith
Elizabeth Smith
ANAnn B. Nattinger
Ann B. Nattinger
PLPurushottam Laud
Purushottam Laud
JNJoan Neuner
Joan Neuner
Background: Theoretically, the estrogen deprivation induced by aromatase inhibitors (AIs) might cause ischemic heart disease, but empiric studies have shown mixed results. We aimed to compare AIs and tamoxifen with regard to cardiovascular events among older breast cancer patients outside of clinical trials. We hypothesized that AIs increase the risk of myocardial infarction.Methods: We identified women age ≥67 years diagnosed with breast cancer from June 30, 2006 to June 1, 2008 in the surveillance, epidemiology, and end results (SEER)‐Medicare database, treated with either tamoxifen or an AI, and followed through December 31, 2012. To compare myocardial infarction (MI) risk for the treatment groups of AIs vs tamoxifen, we developed and assigned stabilized probability of treatment weights and used the Fine and Gray model for time to MI with death not related to MI as a competing risk.Results: Of the cohort of 5648 women, 4690 were treated with AIs and 958 with tamoxifen; a total of 251 patients developed MI, and 22 patients died of MI during the study period while 476 died of other causes. The hazard for MI was not significantly different between AI vs tamoxifen groups (HR = 1.01, 95% CI 0.72‐1.42), after adjusting for the following known MI risk factors at the start of adjuvant therapy: diabetes, ischemic heart disease, congestive heart failure, MI, and peripheral vascular disease.Conclusions: In this SEER‐Medicare‐based population study, there were no significant differences in the risk of MI between AI and tamoxifen users after adjustment for known risk factors.

1 October 1999 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
KNKarin Nelson
Karin Nelson
DWDavid N. Williams
David N. Williams
WAWoubeshet Ayenew
Woubeshet Ayenew
KMKulwant Singh Modi
Kulwant Singh Modi
We describe a case of Staphylococcus lugdunensis pulmonary valve endocarditis in a 65-year-old woman on chronic hemodialysis and provide a review of previously reported cases. The patient presented with fever and altered mental status, but had no other localizing symptoms or signs; coagulase-negative staphylococcus (subsequently identified as S. lugdunensis) was isolated from two sets of blood cultures. Transthoracic and transesophageal echocardiograms showed a large (2.3 × 3.1 cm) vegetation on the pulmonary valve with moderate valvular insufficiency. The patient was treated with 6 weeks of antibiotic therapy and is stable 4 months following the completion of therapy; no surgical intervention was performed. Of the 28 previously reported cases of S. lugdunensis endocarditis, only 1 had previously survived with medical therapy alone. This is the 3rd case report of S. lugdunensis endocarditis in a patient on hemodialysis; the presumed portal of entry in this and previously reported cases was the vascular access device. Endocarditis due to this organism is characterized by a high mortality, rapid tissue destruction, and a predilection for native valves. Because the clinical outcome is much more favorable with valvular replacement, speciation of the organism assumes great importance in defining the therapeutic approach.

1 February 2024 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
MCM. Conroy
M. Conroy
AHA. Harris
A. Harris
MGM. Georgen
M. Georgen
HMH. Min
H. Min
RKR. Kurzrock
R. Kurzrock

1 January 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
ICInna Chervoneva
Inna Chervoneva
APAmy R. Peck
Amy R. Peck
YSYunguang Sun
Yunguang Sun
MYMisung Yi
Misung Yi
SUSameer S. Udhane
Sameer S. Udhane
HRHallgeir Rui
Hallgeir Rui
PURPOSE: T-cell–mediated cytotoxicity is suppressed when programmed cell death-1 (PD-1) is bound by PD-1 ligand-1 (PD-L1) or PD-L2. Although PD-1 inhibitors have been approved for triple-negative breast cancer, the lower response rates of 25%-30% in estrogen receptor–positive (ER+) breast cancer will require markers to identify likely responders. The focus of this study was to evaluate whether PD-L2, which has higher affinity than PD-L1 for PD-1, is a predictor of early recurrence in ER+ breast cancer. METHODS: PD-L2 protein levels in cancer cells and stromal cells of therapy-naive, localized or locoregional ER+ breast cancers were measured retrospectively by quantitative immunofluorescence histocytometry and correlated with progression-free survival (PFS) in the main study cohort (n = 684) and in an independent validation cohort (n = 273). All patients subsequently received standard-of-care adjuvant therapy without immune checkpoint inhibitors. RESULTS: Univariate analysis of the main cohort revealed that high PD-L2 expression in cancer cells was associated with shorter PFS (hazard ratio [HR], 1.8; 95% CI, 1.3 to 2.6; P = .001), which was validated in an independent cohort (HR, 2.3; 95% CI, 1.1 to 4.8; P = .026) and remained independently predictive after multivariable adjustment for common clinicopathological variables (HR, 2.0; 95% CI, 1.4 to 2.9; P < .001). Subanalysis of the ER+ breast cancer patients treated with adjuvant chemotherapy (n = 197) revealed that high PD-L2 levels in cancer cells associated with short PFS in univariate (HR, 2.5; 95% CI, 1.4 to 4.4; P = .003) and multivariable analyses (HR, 3.4; 95% CI, 1.9 to 6.2; P < .001). CONCLUSION: Up to one third of treatment-naive ER+ breast tumors expressed high PD-L2 levels, which independently predicted poor clinical outcome, with evidence of further elevated risk of progression in patients who received adjuvant chemotherapy. Collectively, these data warrant studies to gain a deeper understanding of PD-L2 in the progression of ER+ breast cancer and may provide rationale for immune checkpoint blockade for this patient group.

18 March 2021 in Endocrinology
Verified
Journal Article
Closed access
PDF file
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
AFAmy M Fowler
Amy M Fowler
EWElizabeth Weil
Elizabeth Weil
KWKari B Wisinski
Kari B Wisinski
TTThu H Truong
Thu H Truong
CLCarol Lange
Carol Lange
Although incurable, the prognosis for patients with metastatic breast cancer (MBC) has considerably improved with the approvals of multiple targeted and cytotoxic therapies. For hormone receptor-positive (HR+), i.e., estrogen receptor and progesterone receptor positive (ER+/PgR+) and Human Epidermal Growth Factor Receptor-2 negative (i.e.,ERBB2 gene non-amplified or HER2-) MBC, current approved treatment options include palliative endocrine therapy (ET), Cyclin-Dependent Kinase (CDK 4/6) inhibitors, mTOR inhibitors, and PI3 kinase inhibitors. Most treatments target ER+ disease regardless of PgR status. Although the presence of PgR is crucial for ER+ cell proliferation in both normal and malignant mammary tissue, currently, no approved treatments specifically target PgR. Recent literature has demonstrated, the potential of antiprogestins in the treatment of MBC both in preclinical and clinical studies.Antiprogestins, including selective PgR modulators (SPRMs) that act as PgR antagonists, are a promising class of therapeutics for overcoming endocrine resistance in patients who develop activating estrogen receptor 1 (ESR1) and phosphatidylinositol 3-kinase (PI3K) gene mutations after prior endocrine therapy. Herein, we summarize the role of PgR and antiprogestins in the treatment of MBC. Other aspects on the use of functional imaging, clinical trials incorporating novel antiprogestins and potential treatment combinations to overcome endocrine resistance will be briefly discussed.